A carnosine composition for alleviating atherosclerosis and its application
The carnosine composition inhibits endogenous cholesterol synthesis and exogenous cholesterol absorption, and the problem of limited drug side effects and effects of atherosclerosis treatment in the prior art is solved, and the effect of reducing cholesterol levels and plaque area is achieved, and the aortic atherosclerosis is achieved. Sclerosis provides new treatment pathways.
Patent Information
- Application Number
- CN202411008509.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-26
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-07-26
AI Technical Summary
The prior art has problems with liver and gastrointestinal damage caused by drug use when treating atherosclerosis, and has failed to effectively inhibit endogenous cholesterol synthesis and exogenous cholesterol absorption, resulting in limited therapeutic effects.
Provided a carnosine composition consisting of carnosine, histidine and quercetin, with a weight ratio of 70~85:10~30:4~10, used to inhibit endogenous cholesterol synthesis and exogenous cholesterol absorption, by reducing HMGCR , expression of Surf4, NPC1L1, HNF-1α and HNF-4α genes and proteins, and drugs for the treatment of atherosclerosis are prepared.
The carnosine composition can significantly reduce the TC and LDL-C content in the serum, reduce the plaque area of aortic roots, reduce cholesterol synthesis and absorption, provide a treatment option without side effects, and has the potential to prepare health care products, medical foods or drugs. .
Smart Images

Figure CN118542864B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedicine and relates to a carnosine composition for alleviating atherosclerosis and application thereof. Background Art
[0002] Atherosclerosis is a chronic disease that seriously endangers human health. The causes of atherosclerosis are complex, but dyslipidemia is an independent factor leading to the formation of atherosclerosis. Dyslipidemia refers to elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG), while high-density lipoprotein cholesterol (HDL-C) is reduced. Clinically, TC exceeding 6.2mmol / L is considered hypercholesterolemia; LDL-C exceeding 4.14mmol / L is considered high LDL-C; HDL-C below 1.04mmol / L is considered low HDL-C; TG exceeding 2.26mmol / L is considered high triglyceridemia. The dietary structure of residents has undergone tremendous changes with the improvement of social level, and the continuous increase in residents' fat intake has led to abnormal blood lipids in the body.
[0003] At present, atherosclerosis is mainly treated clinically by drugs, but long-term use of drugs can cause damage to the liver and gastrointestinal tract. Therefore, it is very urgent to find an active natural substance with no side effects to alleviate atherosclerosis.
[0004] Carnosine is a non-protein histidine dipeptide composed of β-alanine and L-histidine. It is mainly found in the skeletal muscles of marine migratory fish, birds and chickens, and has strong antioxidant, anti-inflammatory and anti-glycation activities. It has been reported that carnosine has the effect of lowering blood lipids, but whether carnosine has the effect of inhibiting endogenous cholesterol synthesis, low-density lipoprotein cholesterol secretion and exogenous cholesterol absorption has not been reported. Compared with other existing pathways, if carnosine can inhibit endogenous cholesterol synthesis and exogenous cholesterol absorption, it will solve the problem of dietary restrictions in patients with atherosclerosis from the root. Summary of the invention
[0005] In view of the technical problems existing in the prior art, the present invention provides a carnosine composition for alleviating atherosclerosis and its application. The technical solution of the present invention is specifically as follows.
[0006] In a first aspect, the present invention provides a carnosine composition for alleviating the formation of atherosclerosis, wherein the carnosine composition consists of carnosine, histidine and quercetin.
[0007] Furthermore, in the carnosine composition of the present invention, the weight ratio of carnosine, histidine and quercetin is 70-85:10-30:4-10.
[0008] In a second aspect, the present invention provides a use of a carnosine composition for alleviating the formation of atherosclerosis in the preparation of a drug for preventing atherosclerosis.
[0009] Furthermore, in the application provided by the present invention, the drug prepared from the carnosine composition for alleviating the formation of atherosclerosis inhibits the synthesis of endogenous cholesterol.
[0010] Furthermore, in the application provided by the present invention, the drug prepared from the carnosine composition for alleviating the formation of atherosclerosis inhibits the absorption of exogenous cholesterol.
[0011] In a third aspect, the present invention provides a use of a carnosine composition for alleviating the formation of atherosclerosis in the preparation of a drug for treating atherosclerosis.
[0012] Furthermore, in the application provided by the present invention, the drug prepared from the carnosine composition for alleviating the formation of atherosclerosis reduces the plaque area at the aortic root.
[0013] Furthermore, in the application provided by the present invention, the drug prepared from the carnosine composition for alleviating the formation of atherosclerosis reduces the TC and / or LDL-C content in serum.
[0014] Furthermore, in the application provided by the present invention, the drug prepared by the carnosine composition for alleviating the formation of atherosclerosis alleviates atherosclerosis by reducing the expression of HMGCR and / or Surf4 and / or NPC1L1 and / or HNF-1α and / or HNF-4α genes and / or proteins.
[0015] Furthermore, in the application provided by the present invention, the drug prepared from the carnosine composition for alleviating the formation of atherosclerosis alleviates atherosclerosis by inhibiting the synthesis of endogenous cholesterol and the absorption of exogenous cholesterol.
[0016] Compared with the prior art, the technical solution provided by the present invention has at least the following beneficial effects or advantages:
[0017] The carnosine composition provided by the present invention has the effect of inhibiting endogenous cholesterol synthesis and exogenous cholesterol absorption. HMGCR protein is a key protein for regulating cholesterol synthesis, and Surf4 protein is a key protein for regulating LDL-C secretion, and both are mainly present in the liver. NPC1L1, HNF-1α and HNF-4α proteins are mainly present in the intestine, and they are key proteins for regulating intestinal cholesterol absorption. The present invention has found that the carnosine composition can reduce the expression of HMGCR and Surf4 genes and proteins in the liver and reduce the expression of NPC1L1, HNF-1α protein and HNF-4α gene in the small intestine. It shows that the carnosine composition can inhibit endogenous cholesterol synthesis and exogenous cholesterol absorption by reducing the expression of HMGCR, Surf4, NPC1L1, HNF-1α and HNF-4α proteins.
[0018] In summary, the present invention provides a carnosine composition for alleviating atherosclerosis, which has the beneficial effects of reducing the expression of HMGCR, Surf4, NPC1L1, HNF-1α and HNF-4α genes and proteins, thereby inhibiting endogenous cholesterol synthesis and exogenous cholesterol absorption, and has the potential to prepare health products, medical foods or pharmaceutical compositions, and provides a selective approach for the treatment of atherosclerosis. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 Composition of carnosine for ApoE - / - Effects of the aortic arch plaques on mice. A is the blank group; B is the model group; C is the positive group; D is the combination-low group; E is the combination-medium group; and F is the combination-high group.
[0020] Figure 2 Composition of carnosine for ApoE - / - Effects of serum TC and LDL-C in mice. A is serum TC content; B is serum LDL-C content; C is fecal TC content.
[0021] Figure 3 Composition of carnosine for ApoE - / - Effects of HMGCR gene and protein expression in mouse liver. A is the HMGCR gene; B is the HMGCR protein.
[0022] Figure 4 Composition of carnosine for ApoE - / - Effects of Surf4 gene and protein expression in mouse liver. A is the Surf4 gene; B is the Surf4 protein.
[0023] Figure 5 ApoE - / -Effects of NPC1L1 gene and protein expression in mouse small intestine. A is NPC1L1 gene; B is NPC1L1 protein.
[0024] Figure 6 ApoE - / - Effects of HNF-1α and HNF-4α genes and proteins on the small intestine of mice. A is the HNF-1α gene; B is the HNF-1α protein; C is the HNF-4α gene. DETAILED DESCRIPTION
[0025] The technical scheme of the present invention is described below in conjunction with the embodiments, but the present invention is not limited to the following embodiments. The experimental methods and detection methods described in each embodiment are conventional methods unless otherwise specified; the reagents and materials described are all commercially available unless otherwise specified.
[0026] Example 1
[0027] This example provides the preparation of carnosine and quercetin of a carnosine composition.
[0028] 1. Isolation and extraction of carnosine
[0029] Preparation method of carnosine: Take the meat of bonito and mince it. Add 100 mg of fish meat to 800 mL of pre-cooled deionized water and use a high-speed homogenizer for homogenization. Use 0.1 mol / L sodium bicarbonate solution to adjust the pH of the homogenate, and the pH is controlled between 7.2 and 7.7, and the temperature is controlled within the range of 25 to 30 ° C. Add 5 g of trypsin, 15 g of papain, 3 g of flavor protease and 6 g of neutral protease to the homogenate and stir. After mixing, enzymolysis is carried out at room temperature for 5 hours. After the enzymolysis is completed, the enzymolysis solution is inactivated in a water bath, and the enzymolysis solution is centrifuged at 4 ° C and 8000 rpm for 20 minutes to absorb the supernatant, and then 5% perlite is added for decolorization. Then, a 5000Da ultrafiltration membrane was used for preliminary separation, and then a 1000Da ultrafiltration membrane was used for filtration to collect low molecular peptides. Then, the low molecular peptides were further separated, collected and purified by a C18 reverse phase chromatography column. The purification conditions were 50mmo / L potassium dihydrogen phosphate (pH=7.80): methanol=85:15; flow rate was 0.5mL / min; column temperature was 25℃. Finally, the purified liquid was freeze-dried to obtain carnosine dry powder.
[0030] 2. Isolation and extraction of quercetin
[0031] The preparation method of quercetin comprises the following steps: heating and boiling the flowers of Sophora japonica to obtain a homogenate to obtain a precipitate, dissolving the precipitate with 2% H2SO4, and then distilling the precipitate to collect the quercetin.
[0032] Example 2
[0033] This example provides a method for treating ApoE with carnosine composition. - / - Inhibition of hepatic cholesterol synthesis and intestinal cholesterol absorption in mice.
[0034] The carnosine composition used in this embodiment is composed of a mixture of carnosine, histidine and quercetin in a weight ratio of 70-85:10-30:4-10.
[0035] 1. Experimental Animal Grouping and Management
[0036] 12 C57BL / 6J male mice weighing 20±2g and 60 ApoE - / - Male mice were first given basic feed and distilled water for one week of adaptive feeding under the following conditions: 22±1℃, relative humidity 60±10%, 12h light / dark cycle. Then 12 C57BL / 6J male mice were set as blank group, and all ApoE - / - Male mice were randomly divided into 5 groups, namely, model group, positive group, combination-low group, combination-medium group and combination-high group, with 12 mice in each group. The specific management is shown in Table 1.
[0037] The mouse breeding cycle was 16 weeks. The mice were killed after the 16th week. The mice were fasted and had free access to water for 12 h before being killed. The mice were anesthetized by intraperitoneal injection of sodium pentobarbital (dose 20 mg / kg, concentration 2 mg / mL). After blood was collected from the eyeballs, the mice were killed by cervical vertebrae dislocation, and the serum, liver and small intestine were collected.
[0038] Table 1 Animal experiment design
[0039]
[0040] Note: mg / kgBW·d means mg per kg body weight per day, and 10 mg / kgBW·d means 10 mg per kg body weight per day. The carnosine composition in the above table is composed of carnosine, histidine and quercetin in a mass ratio of 80:12:8, and the dosage of each group is different.
[0041] 2. Index determination
[0042] (1) Determination of lipid accumulation in the aortic arch
[0043] The aorta root is located inside the heart, so the heart was stained with oil red. After collecting the mouse blood, normal saline was injected into the heart until the outflowing normal saline was colorless. The heart was then fixed in 4% paraformaldehyde, embedded in OCT, sliced into 8μm white slices, and then stained with oil red and hematoxylin. Figure 1 A in the blank group ApoE - / - Mouse aortic arch plaques, Figure 1 B in the figure is the model group ApoE - / -Mouse aortic arch plaques, Figure 1 C in the positive group is ApoE - / - Mouse aortic arch plaques, Figure 1 D in the formula is low ApoE - / - Mouse aortic arch plaques, Figure 1 E in the formula is the composition - ApoE in the formula - / - Mouse aortic arch plaques, Figure 1 F in the formula is the composition - high ApoE - / - Mouse aortic arch plaque. Figure 1 The results showed that intervention with different doses of carnosine combination could significantly reduce the plaque area, with the aortic root plaque area reduced by 44.18%, 44.33% and 53.65% respectively.
[0044] (2) Detection of serum TC and LDL-C levels in mice
[0045] The blood was centrifuged at 4°C to obtain serum. The TC and LDL-C levels in serum and feces were measured according to the procedures in Tables 2 and 3. Figure 2 A) and fecal TC ( Figure 2 C) and serum LDL-C ( Figure 2 B) content in the serum and found that the carnosine composition can significantly reduce the TC and LDL-C content in serum and significantly increase the TC content in feces.
[0046] Table 2 TC sample addition steps
[0047]
[0048] Table 3 LDL-C sample addition steps
[0049]
[0050] (3) Determination of HMG-CoA and Surf4 genes in the liver
[0051] Gene extraction from liver: Weigh 0.3g liver sample and add 500uL FreeZol Reagent to grind and let stand for 5min. Then add 200uL Dilution Buffer, mix and let stand for 5min to remove impurities, and finally centrifuge at 4℃ and 11200rpm for 15min, take 550uL supernatant and add an equal volume of isopropanol, repeatedly invert and mix, and let stand at room temperature for 10min. Then centrifuge at 4℃ and 11200rpm for 10min, remove the supernatant, add 1mL of 75% ethanol and centrifuge at 4℃ and 9100rpm for 3min, remove the supernatant, and repeat this step once. Dry the precipitate obtained by centrifugation, and finally add 20uL enzyme-free water to fully dissolve the RNA.
[0052] Reverse transcription of genes: A total volume of 16uL of RNA mixture (RNA + 4×g DNA wipe mix + RNase-freedd H2O) was kept at 42℃ for 2min, then 4uL of 5×Hiscript III qRT SuperMixa solution was directly added to the reaction tube and mixed, and the mixture was kept at 42℃ for 15min and 85℃ for 5 sec.
[0053] Quantification: cDNA was quantified using 2×ChamQ Universal SYBR qPCR Master Mix solution.
[0054] Determination of hepatic HMG-CoA and Surf4 transporters
[0055] Sample processing: Weigh 0.50 g of liver sample, wash with cold PBS to remove blood, add 10 times tissue lysis buffer containing SPMF and phosphatase inhibitors, grind in a grinder for 60 seconds, and then place it on ice for 30 minutes (during this period, repeatedly blow with a pipette to ensure complete lysis), and finally centrifuge it at 4°C 12000r / min for 15 minutes, and aspirate the supernatant.
[0056] Protein concentration determination and denaturation: Determine the concentration of supernatant protein according to the BCA kit instructions, then add 5×SDS loading buffer according to the total volume of protein, mix well, and boil in a metal bath at 100°C for 10 min.
[0057] SDS-PAGE electrophoresis: Fix the electrophoresis gel on the electrophoresis stand and place it in the electrophoresis tank. Add electrophoresis solution to the tank, and add 2 µL of Marker and 8 µL of denatured sample to the sample well. Use a constant voltage of 90 V for electrophoresis for 120 minutes until the Marker reaches the bottom of the electrophoresis gel.
[0058] Western blot: After electrophoresis, cut the gel of the target protein according to the position of the target protein and the marker. Then transfer the membrane at a constant current of 160mA for 28min. Transfer the PVDF membrane to an incubation box pre-filled with rapid blocking solution and block it on a shaker at room temperature for 30min.
[0059] Primary antibody incubation: Add primary antibody (1:500) and incubate in 4°C refrigerator for 12 h.
[0060] Secondary antibody incubation: The primary antibody was recovered and washed with washing solution for 5 times, 5 min each time, and the secondary antibody (1:10000) was added and incubated on a shaker for 2 h. Finally, the immunoreactive bands were observed using chemiluminescence and quantified using Image J 1.8 software.
[0061] The experimental results are as follows Figure 3 As shown, compared with the blank group, ApoE - / - The mouse HMGCR gene ( Figure 3 A) and protein ( Figure 3 B) level was significantly higher than that in the blank group. However, ApoE - / - The HMGCR gene and protein levels of mice were significantly lower than those of the model group, indicating that the carnosine composition can reduce cholesterol levels by inhibiting the expression of HMGCR gene and protein. Figure 4 It can be seen that compared with the model group, different doses of carnosine combination can significantly reduce the expression of Surf4 gene in mice ( Figure 4 A) and protein ( Figure 4 B) levels, indicating that the carnosine composition can reduce serum LDL-C content by regulating Surf4 gene and protein.
[0062] (4) Determination of intestinal NPC1L1, HNF-1α and HNF-4α genes and proteins
[0063] The experimental steps were the same as those in (3) above. - / - Mouse NPC1L1 ( Figure 5 A in), HNF-1α ( Figure 6 in A) and HNF-4α ( Figure 6 C) The expression of ApoE gene was significantly higher than that of the blank group mice, while after intervention with different doses of carnosine combination - / - Mouse ( Figure 5 A in), HNF-1α ( Figure 6 in A) and HNF-4α ( Figure 6 C) Gene expression was significantly reduced, NPC1L1 ( Figure 5 B) and HNF-1α ( Figure 6 The protein content in B) was also significantly reduced.
[0064] Example 3
[0065] This example provides the inhibitory effect of the carnosine composition on blood lipids in patients with atherosclerosis.
[0066] Test substance: the carnosine composition provided by the present invention, which is composed of a mixture of carnosine, histidine and quercetin in a weight ratio of 70-85:10-30:4-10.
[0067] Subjects: Referring to the "Guidelines for Clinical Research of New Chinese Medicines", 130 patients with hyperlipidemia who were treated in the Affiliated Hospital of Guangdong Medical University from April 2023 to May 2024 were selected, and their serum TC and LDL-C levels were retested. Without changing their daily diet, fasting blood was collected once. According to the results of blood sampling, a total of 60 male and female patients with two serum TC averages ≥ 6.2mmol / L and LDL-C averages ≥ 4.14mmol / L were selected. The patients were aged 18 to 60 years old, had no serious diseases such as heart, liver, kidney, hematopoietic system and other metabolic diseases, and had no allergic constitution or allergy to the test samples.
[0068] Experimental plan: 60 patients were divided into treatment group and placebo group by random number table method, with 30 people in each group. There were 15 males and 15 females in the placebo group; there were 17 males and 13 females in the treatment group. Without changing the daily diet, the 30 subjects supplemented 50g fried pork liver (130 kcal / 100g), 100g crispy meat (336.54 kcal / 100g) and 150g fatty pork (807 kcal / 100g) for lunch every day, and then gave the treatment group patients carnosine composition powder for treatment, and gave the placebo group patients placebo powder (main ingredients: histidine, alanine, fructan) for treatment. The treatment duration of the treatment group and the placebo group was 16 weeks. Each patient took 5g once a day, with warm water after breakfast.
[0069] TC content and LDL-C content detection: 4 mL of blood samples were drawn from fasting subjects at the 16th week of treatment and after the 16th week, centrifuged at 3000 r / min for 20 min, and the upper serum was taken and stored at -80°C for testing. After all samples were collected, the serum TC and LDL-C content of the subjects were detected according to the method in Example 1, and the average of the two sampling test results was taken for comparison.
[0070] Test results:
[0071] The results of TC and LDL-C tests are shown in Tables 4 and 5.
[0072] Table 4 Changes in TC content
[0073]
[0074] Table 5 Changes in LDL-C content
[0075]
[0076] As shown in Table 4 and Table 5, the carnosine composition provided by the present invention can significantly reduce the TC and LDL-C content in the patient's serum, indicating that the carnosine composition can regulate high blood lipids caused by a high-fat diet.
[0077] The above test results show that the carnosine composition provided by the present invention has the ability to lower blood lipids in both animal tests and clinical trials.
[0078] The embodiments described above are part of the embodiments of the present invention, but not all of them. The detailed description of the embodiments of the present invention is not intended to limit the scope of the invention claimed for protection, but only represents selected embodiments of the present invention. All other embodiments obtained without creative work and related deductions and substitutions made by ordinary technicians in the field under the conditions of the concept of the present invention belong to the scope of protection of the present invention.
Claims
1. The use of a carnosine composition in the preparation of a drug for alleviating atherosclerosis, characterized in that: The carnosine composition consists of carnosine, histidine and quercetin; The weight ratio of carnosine, histidine and quercetin is 70-85:10-30:4-10.
2. The use of a carnosine composition in the preparation of a drug for preventing atherosclerosis, characterized in that: The carnosine composition consists of carnosine, histidine and quercetin; The weight ratio of carnosine, histidine and quercetin is 70-85:10-30:4-10.
3. The use according to claim 1 or claim 2, characterized in that: The drug inhibits endogenous cholesterol synthesis and inhibits exogenous cholesterol absorption.
4. The use according to claim 1 or claim 2, characterized in that: The drug reduces aortic root plaque area.
5. The use according to claim 1 or claim 2, characterized in that: The drug reduces the TC and / or LDL-C content in serum.
6. The use according to claim 3, characterized in that: The drug inhibits endogenous cholesterol synthesis and exogenous cholesterol absorption by reducing the expression of HMGCR and / or Surf4 and / or NPC1L1 and / or HNF-1α and / or HNF-4α genes and / or proteins.
